An interventional study of Transcutaneous non-invasive vagus nerve stimulation (tVNS) and Sham stimulation in Depressive Disorder, Major, sponsored by University of Bonn. Enrolling by invitation at 1 site in Germany. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-12-04.
Sponsored by University of Bonn · Not applicable, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 164 studies in Depressive Disorder, Major with a site in Germany — 26 open to participants now, 27 under way, 5 of them phase 3. Depressive Disorder, Major · Germany.
Among the 164 studies in Depressive Disorder, Major with a site in Germany, this one is the 109th largest by planned enrollment of the 150 interventional ones that give a count, is one of 10 that started in 2024, is one of 53 with no phase, reaches primary completion later than 6 of the 26 other live ones, and was the 143rd registered.
3,051 studies on the registry are indexed under Depressive Disorder, Major; 596 are open to participants now.
Browse Depressive Disorder, Major studies →26 of the 164 studies in Depressive Disorder, Major with a site in Germany are open now. Recruiting first, the newest first:
Eli Lilly and Company · Sites in Germany, United States, Australia and 12 more countries
Ages 18–75
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico · Sites in Germany, Italy, Spain
Ages up to 45 · Healthy volunteers
University of Regensburg · Sites in Germany
Ages 18–70
Eli Lilly and Company · Sites in Germany, United States, Australia and 12 more countries
Ages 18–75
Cybin IRL Limited · Sites in Germany, United States, Australia and 5 more countries
Ages 18–85
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 419 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 299 (71%) stop at 75 or younger; 55 take children under 18; 100 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
164 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 29 · Phase 3 51 · Phase 4 10
First in 1998; this study’s year is marked. 10 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 80 is close to the median of 80 across 2,535 interventional studies indexed under Depressive Disorder, Major.
Median enrollment 176 across the 150 interventional studies, 104 across the 13 observational. Of the 124 that completed or were terminated, 43 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
80 of 164 have an industry lead sponsor. The 10 most frequent:
University of Bonn is the lead sponsor of 39 studies on the registry; 20 are open to participants now.
University of Bonn has 3 studies filed under Depressive Disorder, Major — fewer than ten, so there is no comparison to draw.
10 of the studies in Depressive Disorder, Major with a site in Germany that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07076407Phase 3Xenon Pharmaceuticals Inc.A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3) | 2027-05 |
| NCT06793397Phase 3Cybin IRL LimitedA Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder | 2027-06-07 |
| NCT06389175University of BonnNon-invasive Vagus Nerve Stimulation as a Tool to Modulate Stomach-Brain Coupling in Depression | 2026-12 |
| NCT07197138Max-Planck-Institute of PsychiatryIMPACT-D+: Immune-Modulating and Psychometric Effects of Accelerated TMS in Depression Plus Comorbid Post-COVID-19 Condition | 2027-01 |
| NCT07065240Seaport TherapeuticsA Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study) | 2027-03 |
Add all 10 to your calendar (.ics) → With an account.
Among the 164 studies in Depressive Disorder, Major with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The overarching goal of the project is to determine whether differences in stomach-brain coupling contribute to key symptoms of major depressive disorder (MDD) and whether transcutaneous non-invasive vagus nerve stimulation (tVNS) may serve as a non-invasive intervention to improve aberrant interoceptive signaling in participants suffering from MDD.
It is planned to conduct a randomized cross-over study including two neuroimaging sessions to assess the effect of acute tVNS (vs. sham) on stomach-brain coupling using concurrent fMRI and EGG. Furthermore, to evaluate potential medium-term effects of repeated applications of tVNS (vs. sham), changes across two weeks in gastric myoelectric frequency and interoception/somatic sensations as well as metabolic and mood states will be evaluated using a combination of lab-based with ecological momentary assessments (EMA).
Consequently, three major hypotheses will be tested:
Hypothesis 1: Participants suffering from MDD show altered stomach-brain coupling compared to matched healthy control participants; inter-individual differences in interoceptive measures/somatic sensations correlate with stomach-brain coupling.
Hypothesis 2: tVNS enhances stomach-brain coupling in a vagal afferent network.
Hypothesis 3: In participants suffering from MDD, tVNS influences interoception/somatic sensations and normalizes gastric myoelectric frequency over an extended stimulation period.
In addition to these main outcomes, tNVS effects on value-based decision-making will be investigated. In detail, participants will be invited to two neuroimaging sessions (T1 and T2) including tVNS or a sham stimulation. At the beginning of each of these sessions, blood will be drawn to determine concentrations of circulating hormones. Afterwards, participants will undergo MRI and complete the following tasks: 1.) Watching an Inscape movie specifically designed to improve imaging at rest. After a 10-minutes baseline scan, tVNS/sham stimulation will start and the Inscape scan is repeated. 2.) Food bidding task to assess neural food cue reactivity as well as bidding behavior and its neural correlates when participants are asked to bid for accessing the presented food. 3.) Foraging task to assess value-based decision-making and its neural correlates with the goal to maximize points in different environments (poor and rich environment). After completing the food bidding and foraging task, the Inscape movie is presented once more to assess tVNS effects after a prolonged stimulation. Throughout all MRI tasks, stomach activity will be assessed by an EGG. Both neuroimaging sessions end with an additional blood draw.
Following the neuroimaging sessions, participants will be invited to two extended stimulation periods (tVNS vs. sham), each lasting approximately two weeks. At the beginning of the extended stimulation periods, participants will be invited to the lab and blood will be drawn (T3). Gastric myoelectric frequency using EGG and value-based decision-making will be assessed at baseline and during stimulation (tVNS or sham). After completing the session, participants are given a tVNS device and are asked to stimulate their vagus nerve for 1.5h at least on four days during the following two weeks. During this time period, participants complete further tasks on value-based decision-making and questionnaires using ecological momentary assessments. In detail, four tasks will cover different aspects of value-based decision making: 1.) Effort allocation task (motivation to work for rewards; completed at T3-T6), 2.) temporal discounting (completed during the whole extended stimulation period), 3.) social discounting (completed during the whole extended stimulation period), and 4.) Influenca (gamified reinforcement learning; completed during the whole extended stimulation period).
After two weeks, participants will again come to the lab and EGG recordings and value-based decision-making tasks will be repeated (T4). Likewise, another blood sample will be collected. The extended stimulation period will then be repeated in the same way for the other stimulation type (tVNS or sham), including both sessions in the lab (T5 and T6). The order of tVNS and sham stimulation is randomized for both neuroimaging sessions as well as the extended stimulation period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All participants will receive tVNS and sham stimulation in a randomized order.
Device: Transcutaneous non-invasive vagus nerve stimulation (tVNS) · Device: Sham stimulation
All participants will receive tVNS and sham stimulation in a randomized order.
Device: Transcutaneous non-invasive vagus nerve stimulation (tVNS) · Device: Sham stimulation
Participants receive tVNS during the neuroimaging sessions and the extended stimulation period. To stimulate vagal afferents, the electrode will be placed at the cymba conchae of the right ear using a previously established, conventional stimulation protocol (25 Hz, 30s on/30s off cycle; NEMOS device, Cerbomed, Erlangen, Germany). To improve blinding, the stimulations intensities will be adjusted to correspond to a mild pricking sensation for tVNS and sham. The extended stimulation period in the experimental group involves six sessions with at least 1.5h of stimulation (stimulation in the lab or at home with home device using the same stimulation protocol as during the neuroimaging sessions; tVNS R device, tVNS Technologies GmbH, Erlangen, Germany).
The control intervention consists of a sham stimulation. In the neuroimaging session the electrode will be placed upside down to stimulate the earlobe, which is not innervated by vagal afferent fibers. To improve blinding, the same stimulation protocol as for the tVNS will be applied (25 Hz, 30s on/30s off cycle; NEMOS device, Cerbomed, Erlangen, Germany) and stimulation intensities will be adjusted to correspond to a mild pricking sensation. During the extended stimulation period, the electrode will be placed at the cymba conchae, but only receive a low-intensity stimulation below the perception threshold (0.1mA). To ensure blinding, participants will be instructed that the extended stimulation period will examine the effects of a low- vs. high-intensity tVNS protocol. Each repeated stimulation period will involve six sessions with at least 1.5h of low-intensity stimulation (stimulation in the lab or at home with home device; tVNS R device, tVNS Technologies GmbH, Erlangen, Germany).
Stimulation-induced acute changes in stomach-brain coupling
Stomach-brain coupling will be assessed using phase-locking values (PLV) at baseline and during tVNS/sham stimulation concurrent to electrogastrogram (EGG) measurements in the MRI. PLV will be compared between groups (HC, MDD) and stimulation conditions (tVNS, sham) with a focus on core regions of the gastric network (postcentral gyrus, cingulate gyrus, precuneus, occipital cortex, fusiform gyrus, inferior frontal gyrus, inferior and superior parietal lobe, thalamus, and inferior cerebellum) and the vagal afferent pathway (nucleus of the solitary tract (NTS), ventral tegmental area (VTA), substantia nigra, hypothalamus, amygdala, putamen, caudate, nucleus accumbens, hippocampus, insula, ventromedial prefrontal cortex, lateral orbitofrontal cortex, dorsal anterior cingulate cortex). PLV will be correlated with self-reported interoception, somatic symptoms, and depressive symptoms (see below).
Time frame: During MRI scan (up to 120 minutes)
Stimulation-induced acute changes in gastric motility
The gastric myoelectric frequency will be assessed during the MRI sessions at baseline and during tVNS and sham stimulation using an EGG. Acute changes in gastric peak frequency will be compared between groups (HC, MDD) and stimulation conditions (tVNS, sham).
Time frame: During MRI scan (up to 120 minutes)
Stimulation-induced mid-term changes in gastric motility
The gastric myoelectric frequency will be assessed at the beginning and end of the extended stimulation periods using an EGG. Data will be collected at baseline and during tVNS and sham stimulation and mid-term changes in gastric peak frequency from the beginning to the end of the extended stimulation periods will be compared between groups (HC, MDD) and stimulation conditions (tVNS, sham).
Time frame: Pre- and post comparison after approx. 2 weeks (beginning and end of extended stimulation period)
Stimulation-induced mid-term changes in self-reported interoception
Interoception is assessed by using the Multidimensional Assessment of Interoceptive Awareness questionnaire, version 2 (MAIA-2). Changes in awareness of bodily sensations will be assessed from the beginning to the end of the extended stimulation period and compared between groups (HC, MDD) and stimulation conditions (tVNS, sham).
Time frame: Pre- and post comparison after approx. 2 weeks (beginning and end of extended stimulation period)
Stimulation-induced mid-term changes in somatic symptoms
The Patient Health Questionnaire-15 (PHQ-15) will be used as self-report measurements to assess changes in severity of somatic symptoms from the beginning to the end of the extended stimulation periods. Changes across time will be compared between groups (HC, MDD) and stimulation conditions (tVNS, sham).
Time frame: Pre- and post comparison after approx. 2 weeks (beginning and end of extended stimulation period)
Stimulation-induced mid-term changes in depressive symptoms
The Beck's Depression Inventory (BDI-II) will be used to assess changes in depressive symptoms from the beginning to the end of the extended stimulation periods. Changes across time will be compared between groups (HC, MDD) and stimulation conditions (tVNS, sham).
Time frame: Pre- and post comparison after approx. 2 weeks (beginning and end of extended stimulation period)
Stimulation-induced acute neural changes in food cue reactivity
Brain activity (BOLD signal) in response to food stimuli (contrasted with office supplies) and during exerting effort on a grip force device will be analyzed by focusing on brain regions associated with the vagal afferent pathway. Brain activity will be compared between groups (HC, MDD) and stimulation conditions (tVNS, sham).
Time frame: During MRI scan of a food bidding task (~13 minutes)
Stimulation-induced acute behavioral changes in invigoration
Invigoration related to food stimuli (contrasted with office supplies) will be operationalized via the relative effort exerted on a grip force device. Invigoration will be compared between groups (HC, MDD) and stimulation conditions (tVNS, sham).
Time frame: During MRI scan of a food bidding task (~13 minutes)
Stimulation-induced acute neural changes during foraging
Brain activity (BOLD signal) during a foraging task will be analyzed by focusing on brain regions associated with the vagal afferent pathway. Brain activity will be compared between groups (HC, MDD) and stimulation conditions (tVNS, sham).
Time frame: During MRI scan of a foraging task (~25 minutes)
Stimulation-induced acute behavioral changes in foraging decisions
Decisions to accept or reject an offered option during a foraging task will be compared between groups (HC, MDD) and stimulation conditions (tVNS, sham). Analyses will focus on acceptance rates during different environments (poor and rich environment) for options differing in the effort needed to accept the option and the earned outcome and learning parameters based on trial-to-trial choices.
Time frame: During MRI scan of a foraging task (~25 minutes)
Stimulation-induced mid-term changes in positive and negative affect
Mood will be assessed during the extended stimulation periods via visual analogue ratings (0-100) in ecological momentary assessments. Mood will be surveyed by using items of the Positive and Negative Affect Schedule (PANAS). Changes will be compared between groups (HC, MDD) and stimulation conditions (tVNS, sham).
Time frame: During extended stimulation period (up to approx. 2 weeks)
Stimulation-induced mid-term changes in self-reported interoception
Participants are asked to indicate their physical sensations on a body silhouette by marking the areas of the body where they perceive activation or deactivation. Interoception is further assessed by using the Visceral Sensitivity Index (VSI). Changes in awareness of bodily sensations will be assessed from the beginning to the end of the extended stimulation period and compared between groups (HC, MDD) and stimulation conditions (tVNS, sham).
Time frame: Pre- and post comparison after approx. 2 weeks (beginning and end of extended stimulation period)
Stimulation-induced mid-term changes in motivation
Motivation will be assessed using the effort allocation task at the beginning and the end of the extended stimulation period. Motivation will be operationalized using button press frequency to gain food and monetary rewards. Changes in motivation will be compared between groups (HC, MDD) and stimulation conditions (tVNS, sham).
Time frame: Pre- and post comparison after approx. 2 weeks (beginning and end of extended stimulation period)
Stimulation-induced mid-term changes in physical activity
Participants will be asked to wear a smartwatch counting steps and fill out the International Physical Activity Questionnaire (IPAQ) to assess changes in physical activity from the beginning to the end of the extended stimulation periods. Changes will be compared between groups (HC, MDD) and stimulation conditions (tVNS, sham).
Time frame: During extended stimulation period (up to approx. 2 weeks)
Stimulation-induced mid-term changes in heart rate
Participants will be asked to wear a smartwatch to assess changes in heart rate and heart rate variability from the beginning to the end of the extended stimulation periods. Changes will be compared between groups (HC, MDD) and stimulation conditions (tVNS, sham).
Time frame: During extended stimulation period (up to approx. 2 weeks)
Stimulation-induced acute changes in blood parameters
Changes in circulating hormones (e.g., insulin, ghrelin, leptin, glucagon-like peptide-1, cholecystokinin, gastric inhibitory polypeptide) and immune parameters (e.g., C-reactive protein, interleukin 6) will be assessed from blood samples before and after tVNS/sham stimulation during the neuroimaging sessions. Changes will be compared between groups (HC, MDD) and stimulation conditions (tVNS, sham). Furthermore, the association of blood parameters with the PLV of the stomach-brain analysis will be evaluated.
Time frame: Before and after stimulation/MRI scan (up to three hours)
Stimulation-induced mid-term changes in blood parameters
Changes in circulating hormones (e.g., insulin, ghrelin, leptin, glucagon-like peptide-1, cholecystokinin, gastric inhibitory polypeptide) and immune parameters (e.g., C-reactive protein, interleukin 6) will be assessed from blood samples at the beginning and end of the extended stimulation period. Changes will be compared between groups (HC, MDD) and stimulation conditions (tVNS, sham).
Time frame: Pre- and post comparison after approx. 2 weeks (beginning and end of extended stimulation period)
Stimulation-induced mid-term changes in composition of microbiome
The bacterial composition of the microbiome as well as the relative frequency of bacterial strains and short-chain fatty acids in the stool will be examined at the beginning and the end of the extended stimulation periods. The first stool sample will be assessed at the beginning of the first stimulation period and a second stool sample will be assessed at the end of the first stimulation period. A this sample will be assessed at the end of the second stimulation period. Changes will be compared between groups (HC, MDD) and stimulation conditions (tVNS, sham).
Time frame: Pre- and post comparison after approx. 2 weeks (beginning and end of extended stimulation period)
Stimulation-induced mid-term changes in discounting-related decision-making
Changes in decision-making during the extended stimulation period will be measured using ecological momentary assessment encompassing temporal and social discounting tasks. Changes will be compared between groups (HC, MDD) and stimulation conditions (tVNS, sham).
Time frame: During extended stimulation period (up to approx. 2 weeks)
Stimulation-induced mid-term changes in reward learning
Changes in reward learning parameters during the extended stimulation period are measured using ecological momentary assessment encompassing a gamified reinforcement learning task (Influenca). Changes will be compared between groups (HC, MDD) and stimulation conditions (tVNS, sham).
Time frame: During extended stimulation period (up to approx. 2 weeks)
Stimulation-induced mid-term changes in loneliness
Changes in self-reported loneliness during the extended stimulation period are measured using ecological momentary assessment. Changes will be compared between groups (HC, MDD) and stimulation conditions (tVNS, sham).
Time frame: During extended stimulation period (up to approx. 2 weeks)
Stimulation-induced mid-term changes in sleep
Participants will be asked to wear a smartwatch to assess changes in sleep (bedtime, rise time, sleep cycles) from the beginning to the end of the extended stimulation periods. Changes will be compared between groups (HC, MDD) and stimulation conditions (tVNS, sham).
Time frame: During extended stimulation period (up to approx. 2 weeks)
Plan to share: Yes — After the publication of the key results of the study, all anonymized imaging data will be made publicly available (e.g., at openfmri.org)
Supporting information: Study protocol, Statistical analysis plan, Analytic code
Time frame: Data will become available after an embargo period of 12 months after completion of the study
Access criteria: Until the data is publicly available, researchers may contact the lead PI to gain access.
Data sharing details ↗ · neuromadlab.com
No publications or documents are linked to this record.
Started May 2024 (actual). Primary completion is estimated for Dec 2026, 31 months after the start.
Of 654 non-industry interventional studies with no phase under Depressive Disorder, Major, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 55. This study's planned 31 months is below that.
Counting every sponsor, half of 694 studies reached it within 33 months; a quarter within 17 and three quarters within 55.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Bonn